Background-C-reactive protein (CRP) may have proatherogenic but also vasoprotective properties. We tested the hypothesis that the configuration of CRP (pentameric, or native [nCRP], versus monomeric, or modified [mCRP]) determines these different characteristics in an in vivo model. Methods and Results-We investigated the effects of human nCRP and mCRP on the development of atherosclerosis in apolipoprotein E-knockout (ApoE Ϫ/Ϫ ) mice. Treatment with nCRP for 8 weeks (2.5 mg/kg SC weekly) resulted in a 4-fold-higher mean aortic plaque area in 14-week-old female ApoE Ϫ/Ϫ mice compared with the saline controls. In contrast, mean plaque size was decreased by Ϸ50% in mCRP-treated ApoE Ϫ/Ϫ mice (2.5 mg/kg SC weekly). Using immunohistochemistry, we report the natural presence of the mCRP antigen in saline controls. mCRP antigen was expressed in smooth muscle cells and extracellularly in the vicinity of the plaques to a similar level in both CRP-treated groups and saline controls. mCRP and ApoB colocalized with macrophages and were equally upregulated in all aortic plaques. Vascular cell adhesion molecule expression was increased, and CD154 and intercellular adhesion molecule showed a trend for higher expression in nCRP-treated compared with mCRP-treated mice. CD154 expression in the vessel wall and plaque size correlated significantly. mCRP-treated ApoE Ϫ/Ϫ exhibited higher serum levels of the antiinflammatory interleukin-10 compared with the other 2 groups. Conclusions-Here, we show that mCRP and nCRP have opposite effects on atherosclerosis in ApoE Ϫ/Ϫ mice. These data may explain in part the conflicting activities previously reported for CRP in models of atherogenesis. (Circulation. 2005;112:1016-1023.)
C -reactive protein (CRP) represents one of the strongest independent predictors in cardiovascular disease in several settings. 1, 2 Originally considered to be an innocent bystander, numerous reports suggest that it plays an active part in the development of vascular inflammation (for review, see elsewhere 3, 4 ). Proinflammatory effects on cardiovascular cells include activation of the complement system, 5 decrease in NO release, 6 and upregulation of cell adhesion molecules. 7 However, CRP also elicits effects considered to be vasoprotective such as endothelium-independent vasorelaxing effects in human vessels in vitro. 8 Verma et al 6 showed that CRP inhibited both basal and vascular endothelial growth factor (VEGF)-stimulated angiogenesis, which would in turn inhibit plaque neovascularization.
These opposing observations may result partly from differences in CRP configuration. The classically studied serum CRP is reported to be a pentamer composed of 5 identical globular subunits arranged as an annular disk (referred to here as native [nCRP] ). 9 nCRP can undergo subunit dissociation into individual monomeric units, eg, when associating with a cell membrane. 10 These subunits undergo a conformational change that significantly modifies CRP structure, solubility, and antigenicity. This form of CRP is called modified or monomeric CRP (mCRP). mCRP is a naturally occurring stable protein but, in contrast to nCRP, is not found in serum but in fibrous tissues of normal human blood vessel intima. 11 The formation of mCRP from CRP is nonproteolytic and irreversible. 12 Numerous studies have identified CRP mRNA expression in many different extrahepatic cells such as islet cells of the pancreas, 13 neurons, 14 adipocytes, 15 and renal tubular epithelial cells. 16 Whether the "CRP" that is translated at each site is the nCRP conformer or the mCRP conformer needs to be clarified.
Recently, Paul et al 17 showed that human CRP transgene expression caused accelerated atherosclerosis in apolipoprotein E-knockout (ApoE Ϫ/Ϫ ) mice, a hypercholesterolemic mouse model of accelerated atherosclerosis. The aim of the present study was to compare the effects of human nCRP and mCRP on the development of early atherosclerosis by using directly injected proteins, thereby testing the hypothesis that the configuration of CRP may determine different effects on atherosclerosis. Using immunohistochemistry, we studied proinflammatory mediators thought to initiate atherosclerosis such as vascular cell adhesion molecule (VCAM), intracellular adhesion molecule (ICAM), and the CD40 ligand CD154, a member of the tumor necrosis factor gene superfamily. Furthermore, to elucidate the role of CRP within the plaque, immunostainings for mCRP, nCRP, ApoB, and macrophages were performed. Finally, cytokines in the serum that activate (interferon [IFN]-␥) and inhibit (interleukin [IL]-10) macrophages were measured.
Methods

Animal Model
Female homozygous ApoE Ϫ/Ϫ mice and their genetic background mice (C57BL/6) were obtained from Jackson Laboratories (Bar Harbor, Maine) at 6 weeks of age. They were maintained in a lightand temperature-controlled environment and had free access to water and standard laboratory chow containing 4% fat (Altromin). Weightmatched ApoE Ϫ/Ϫ and C57BL/6 mice (nϭ7) were randomly assigned to 3 treatment groups: Group 1 received human nCRP 2.5 mg/kg SC; group 2 received a recombinant form of human mCRP 2.5 mg/kg SC; and group 3 received 0.9% saline as control (identical volume given subcutaneously). Treatment was applied once weekly for 8 weeks. Animal weight was determined every week. Before the fifth injection, 50 L whole blood was collected from the tail vein for white blood cell count.
At 14 weeks of age, mice were anesthetized with ketamine (100 mg/kg) and xylazine-HCl (4 mg/kg), and blood samples (between 200 and 250 L) were collected from the vena cava for lipid analysis. Heart and aorta were carefully removed and fixed in 10% buffered formalin for morphometric analysis and immunohistochemistry. All experiments and measurements were performed in accordance with national guidelines for the care and use of research animals.
CRP Preparations nCRP
Crude CRP was purchased from SeraCare Inc. It was bound to Q-Sepharose FF and was eluted with a step gradient of NaCl. Eluted protein was pooled, and CaCl 2 was immediately added to a concentration of 2 mmol/L. The ion exchange step with CRP preparations is critically important not only to reduce endotoxin but also to remove any mCRP protein that may be present in an nCRP preparation. mCRP will strongly bind to the agarose resin. It resists elution with increasing salt concentration but elutes with 5 mol/L guanidinium hydrochloride. Eluted nCRP protein was dialyzed against 25 mmol/L-Tris-HCl and 0.15 mol/L NaCl (pH 7.4) containing 2 mmol/L CaCl 2 , sterile filtered, and stored at 4°C. Storage in calcium-containing buffers is critical to prevent the spontaneous formation of mCRP from nCRP. mCRP mCRP was prepared from nCRP by urea chelation as described previously. 18 By electron microscopic analysis, mCRP molecules in the absence of added salt associate into a diffuse matrix distinct from the annular pentameric disk that defines nCRP. In a normal saline solution, mCRP forms an insoluble suspension of self-aggregated subunits. A recombinant form of mCRP (r m CRP) with both cysteine residues mutated to alanine residues and with an added N-terminal formylmethionine residue was expressed in Escherichia coli and isolated from inclusion bodies to Ͼ95% purity. To facilitate purification of r m CRP, it was acylated with citraconic anhydride to enhance solubility (C-r m CRP). C-r m CRP was directly comparable to mCRP as analyzed by SDS-PAGE, amino acid composition, and N-terminal sequence analysis. Once purified, the citraconyl groups were removed from C-r m CRP by dialysis at room temperature for 20 hours in 0.1 mol/L citrate (pH 3.5). The decitraconylated protein (Cx-r m CRP) was dialyzed extensively at 4°C against 25 mmol/L sodium PBS without calcium (pH 7.4), yielding an insoluble suspended protein similar to mCRP in saline-based buffers. This form was used in the present study. Monoclonal antibodies directed against the C-terminal octapeptide of the CRP subunit (mAb 9C9), which is expressed only in mCRP and not in nCRP, reacted with the same specificity and affinity with mCRP, C-r m CRP, and Cx-r m CRP.
Biochemistry
White blood cell counts were determined automatically with the Coulter method (Beckman) designed for small sample volumes. Serum cholesterol and triglycerides were measured enzymatically. For quantification of lipoprotein cholesterol, 30 L serum was subjected to agarose gel electrophoresis, followed by enzymatic staining of cholesterol as previously described. 19 IFN-␥ and IL-10 levels in the serum of ApoE Ϫ/Ϫ mice were measured by ELISA in duplicates using commercially available kits (Mouse Quantikine ELISA kits, R&D Systems Inc).
Morphological Evaluation
Morphometric analysis of the aorta was performed by planimetry and a semiautomatic image analyzing system (AnalysisPRO, SIS), combined with a counting grid eyepiece for defined movement over the section plane (Zeiss Co) at a magnification of ϫ400 as described previously. 20 Contours of aortic plaques in the aortic root through the aortic valve and in the aortic arch were marked manually with a cursor, and plaque area was automatically calculated. All investigations were performed in a blinded manner.
Immunohistochemistry
Immunohistochemistry was performed on paraffin sections with the following antibodies: rabbit anti-human-CD154 (Santa Cruz Biotechnology, 1:600), rabbit anti-mouse-ApoB48/100 (USBiological, 1:500), rat anti-mouse-macrophages/monocytes (MAB1852, Chemicon International Inc, 1:25), goat anti-human-VCAM-1 (Santa Cruz Biotechnology, 1:300), goat anti-mouse-ICAM-1 (Santa Cruz Biotechnology, 1:100), and 2 mouse anti-human-CRP antibodies as previously described, 21 which were provided by L.A. Potempa: mAb 9C9, which reacts exclusively with mCRP, and mAb 8D8, showing only reactivity with nCRP. Briefly, freshly cut 4-m sections were mounted on silane-coated slides, deparaffinized, and rehydrated through a graded ethanol series, followed by blocking of nonspecific binding with 3% H 2 O 2 (20 minutes, room temperature). An antigen retrieval was performed by heating the slides in citrate buffer (20 minutes in a microwave at 900 W). For antigen visualization, the CSA Dako and Goat Vectastain Elite ABC kits with AEC as the substrate (CD154, VCAM, and ICAM stainings, red deposits), the Rat and Rabbit Vectastain Elite ABC, and the MOM Vectastain kits (Vector Labs) with DAB and histogreen as substrates (CRP and macrophage stainings, brown deposits; ApoB staining, green deposits) were used. Color development was stopped by adding water, and sections were finally counterstained with hematoxylin. Negative controls were performed by omitting the primary antibody. Specific blocking experiments were carried out by preincubating mAb 9C9 and 8D8 with a 10-fold excess of the respective antigens. A double staining was performed with mAb 9C9 as the first and anti-ApoB as the second antibody. The sections were examined under light microscopy at a magnification of ϫ400 with a semiquantitative scoring system (0 to 4): 0ϭno expression, 1ϭmild expression, 2ϭmoderate expression, 3ϭstrong expression, and 4ϭvery strong expression. At least 5 animals per group were stained. All analyses were performed in a blinded manner.
Statistical Analysis
Data are presented as meanϮSEM. For comparisons between treatment groups, the Kruskal-Wallis H test for nonnormally distributed variables was performed. Bivariate regression and correlation analyses were performed by use of the Spearman rank method. A value of PϽ0.05 was considered statistically significant. Data analysis was performed with the SPSS/PCϩ package (SPSS Inc).
Results
Animal Data
Initial body weights were not different between groups. At the end of the study, no differences in body weights were detectable among the ApoE Ϫ/Ϫ groups (17.1Ϯ1.6, 17.3Ϯ1.6, and 17.3Ϯ1.6 g for saline, nCRP, and mCRP, respectively), whereas mCRP-treated C57BL/6 control mice (18.8Ϯ1.8 g) were slightly heavier compared with the other 2 groups (saline and nCRP, both 17.9Ϯ1.7 g; PϽ0.05). Other 3-month-old ApoE Ϫ/Ϫ mice in the animal facility receiving a normal chow had similar body weights. Animals treated with either form of CRP showed no difference in activity or behavior compared with their controls.
Biochemistry
White blood cell counts were identical in all ApoE Ϫ/Ϫ and C57BL/6 groups (data not shown), indicating that no treat-ment induced a systemically detectable inflammatory response. In all ApoE Ϫ/Ϫ groups, IFN-␥ levels in the serum were below the detection limit of Ϸ4 pg/mL. In contrast, all ApoE Ϫ/Ϫ mice had detectable serum IL-10 levels Ͼ4 pg/mL (14Ϯ3, 10Ϯ2, and 26Ϯ11 pg/mL for saline, nCRP, and mCRP, respectively; range, 5 to 92 pg/mL). All control C57BL/6 mice had IL-10 levels Ͼ20 pg/mL (35Ϯ4 pg/mL; range, 21 to 49 pg/mL; PϽ0.01 between control C57BL/6 and control ApoE Ϫ/Ϫ mice). In Table 1 , results are presented according to low (Ͻ10 pg/mL), middle (Ն10 and Ͻ20 pg/mL), and high (Ն 20 pg/mL) IL-10 levels. Significant differences were observed between groups of ApoE Ϫ/Ϫ mice (PϽ0.05). Although control ApoE Ϫ/Ϫ mice had equally distributed IL-10 levels, all mCRP-treated ApoE Ϫ/Ϫ mice exhibited IL-10 levels in the middle and upper ranges, whereas IL-10 levels of all nCRP-treated ApoE Ϫ/Ϫ mice were Ͻ20 pg/mL. Total cholesterol and triglycerides levels, as well as the lipoprotein profiles, were unaffected by either nCRP or mCRP treatment in various groups of ApoE Ϫ/Ϫ mice ( Table 2 ).
Histology and Morphology
Aortic Root
In the aortic root, all ApoE Ϫ/Ϫ mice developed early atherosclerotic lesions characterized by the predominance of foam cells accumulating in the subendothelial space, with no obvious changes in the underlying intima (Figure 1a through 1c). However, treatment with nCRP resulted in 4-fold-higher mean aortic plaque area in the aortic root in ApoE Ϫ/Ϫ mice compared with controls (38.6Ϯ18.3 versus 9.7Ϯ4.0ϫ10 3 m 2 ), and 2 of 7 animals had much larger aortic plaques of 62.5 and 136.9ϫ10 3 m 2 . In contrast, mean plaque area was decreased by Ϸ50% in ApoE Ϫ/Ϫ mice treated with mCRP compared with controls (4.2Ϯ1.3 versus 9.7Ϯ4.0ϫ10 3 m 2 ). Differences between the 3 groups were statistically significant (PϽ0.05; Figure 2 ).
Aortic Arch
The same trend within the groups was observed when plaque area in the aortic arch was quantified, although statistical significance was not reached (4.0Ϯ1.4 and 1.5Ϯ0.9 versus 2.8Ϯ0.8ϫ10 3 m 2 for nCRP, mCRP, and saline, respectively; 0.2ϾPϾ0.05). No lesions were detectable in the control C57BL/6 mice.
Immunohistochemistry
All aortic plaques in ApoE Ϫ/Ϫ mice showed strong and equally distributed CD154 staining (Figure 3b ). In endothe-lium and vascular smooth muscle cells without plaque (Figure 3a) , a moderate CD154 signal was present in a speckled pattern in saline-and nCRP-treated ApoE Ϫ/Ϫ mice. In most mCRP-treated ApoE Ϫ/Ϫ mice, the CD154 signal was weaker in nonlesion areas (Figure 3c ). However, mean scoring values did not differ significantly between the groups. In contrast, there was a significant correlation (Rϭ0.46, PϽ0.05) between plaque size in the aortic root and CD154 expression in intima and media in ApoE Ϫ/Ϫ mice (Figure 4 ). Immunostainings for ICAM (Figure 3d through 3f) and VCAM (Figure 3g through 3i) showed an increased signal in the endothelium of plaque and nonplaque lesions of nCRP-treated ApoE Ϫ/Ϫ mice compared with the other 2 groups. For VCAM stainings, differences were statistically significant. An mCRP antigen was detected in all plaques of CRP-treated ApoE Ϫ/Ϫ mice (Figure 1h and 1i) and could be localized to foam cell cytoplasma. No difference in staining intensity was observed between groups. mCRP antigenic reactivity in all animals, regardless of treatment, also occurred with equal intensity in the vessel wall. It was found in the intima and media, mainly in the cytoplasma of smooth muscle cells, but also extracellularly (Figure 1g , detail). The mCRP signal could be completely blocked when mAb 9C9 was preincubated with an excess of (insoluble) human mCRP before application (data not shown). When neighboring plaque sections were stained with mAbs 9C9 (mCRP) and 8D8 (nCRP), the cytoplasma of foam cells stained strongly for mCRP, whereas nCRP staining was absent or faint. Within the plaque nCRP antigenicity was localized to the interstitium. The overall signal for nCRP was much weaker than for mCRP (Figure 5e and 5f). All plaques stained strongly for ApoB. Macrophages were abundant and similarly expressed in the subendothelial area of atherosclerotic lesions of ApoE Ϫ/Ϫ mice (Figure 1d  through 1f ). Double staining of mCRP and ApoB confirmed colocalization of both antigens in foam cells, areas where macrophage staining also occurred (Figure 5a through 5d ).
Comparison of parallel mCRP-and macrophage-stained sections (Figure 5a and 5d ) revealed that more foam cells were mCRP than macrophage positive. Immunostaining data are summarized in Table 3 .
Discussion
In this study, we show that 2 clearly defined different conformers of human CRP cause opposite effects in an animal model of early atherosclerosis. nCRP increased and mCRP reduced plaque formation in ApoE Ϫ/Ϫ mice with early lesions, processes that may involve the production of the antiinflammatory cytokine IL-10, the proinflammatory cytokine CD154, and the expression of VCAM and ICAM. The role that CRP plays in vivo with respect to acceleration or inhibition of atherogenesis is an important issue. In recent years, a multitude of in vitro data have been generated showing proatherogenic effects of CRP (for review, see elsewhere 3, 4 ). We propose that it is essential to address several methodical aspects in interpreting these data. First, previous studies have neither discussed nor distinguished the observed effects in terms of 2 distinct conformational forms of CRP. Because prolonged storage of purified CRP in the absence of calcium or in the presence of chelating agents will cause a spontaneous conversion of nCRP to mCRP, this issue is most relevant. 22 Because mCRP does not require fragmentation of the nCRP protein, an SDS-PAGE assay to define the "purity" of a nCRP preparation would be insufficient to prove that there is no mCRP in such preparations. Second, many, if not all, CRP-polyclonal antisera contain specificity to both the nCRP antigen and mCRP antigen. 23 Also, monoclonal anti-CRP-clone 8 has clearly been shown to detect predominantly the mCRP protein and not the nCRP protein. 24 Hence, any immunohistological studies evaluating tissue-associated CRP may, in fact, more accurately report on the expression of tissue associated mCRP. Third, many previously reported studies using CRP used test protein concentrations Ͼ5 g/mL. Using high concentrations of CRP protein would favor the effects of any minor component found in any isolated preparation. In the present study, we tried to take these limiting factors into consideration.
Three recently published in vivo studies support an active role of human CRP in vascular injury in mice. First, arterial injury in human CRP-transgenic mice resulted in a higher rate of thrombosis. 25 Second, human CRP-transgenic mice crossed with ApoE Ϫ/Ϫ mice developed accelerated atherosclerosis. 17 Third, in rats, injection of human CRP enhanced tissue damage in myocardial infarction. 26 The last 2 studies described immunohistochemical expression of human CRP in the tissue. Our finding that nCRP accelerated plaque formation in ApoE Ϫ/Ϫ mice is in line with the results of the above-mentioned models. However, our model differs in several important ways. Concern has been addressed through the use of heterologous systems. 27 Exposing mice to huge 28 reported that when mice were injected with 100 g IV (Ϸ5 mg/kg) of mCRP, little or no mCRP was detected in a number of serum specimens. Because mCRP is hydrophobic and thus tends to self-aggregate, its movement away from the injection site as a free protein is unlikely. The mCRP antigenic reactivity found in the plaques of all mouse aortas could reflect the natural presence of mouse mCRP. We did not directly determine to what extent the mAb 9C9 antibody also recognizes mouse "CRP" epitopes. But because the primary structure of mouse CRP is known to be 70% homologous to human CRP 29 and residues 201 to 205 (KPQLW), which define the epitope for mAb 9C9 specificity, 21 are conserved in human and mouse CRP, 9 it is highly likely that a naturally occurring form of mouse mCRP exists. The facts that saline-treated ApoE Ϫ/Ϫ mice also stained positively and that antibody reactivity could be completely adsorbed with the human mCRP protein also suggest that human and mouse proteins are structurally similar. Our animal model identifies, for the first time, the existence of a mouse mCRP protein that is found at vessel walls and sites of atherogenic plaque buildup. Furthermore, plaque development is regulated by injection of human CRP proteins at distant tissue sites.
Staining of mCRP could be attributed to the cytoplasma of foam cells. In an in vitro study, it was proposed that CRP aggregates may bind and cluster LDL particles phagocytized by macrophages, leading to foam cell formation. 30 The colocalization of mCRP, ApoB, and macrophages found here supports this hypothesis. Comparison of nCRP and mCRP staining in the plaque showing a predominance of mCRP reactivity within the foam cells suggests that CRP aggregates are related to the modified isoform of CRP. Extrahepatic expression of CRP in smooth muscle cells has been described. 31, 32 However, whether mCRP is locally produced or derived from serum CRP needs to be clarified. The lack of mCRP staining in normal vessel sections without plaque formation is in contrast to previous findings in humans in whom it is constitutively expressed in several healthy tissues. 11 Further studies are needed to determine the exact role of mouse mCRP at the site of plaque development. However, the presence of mCRP in the vessel wall as soon as plaques develop suggests an important role in early atherogenesis in mice.
Extending previous work by Paul et al, 17 who showed proatherogenic effects of CRP in ApoE Ϫ/Ϫ mice with wellestablished lesions, our animal model starting with CRP injections as early as 6 weeks, before lesions were established, suggests effects on early atherogenesis. To provide further evidence for this assumption, we studied proinflammatory pathways involved in the initiation of the disease, ie, expression of VCAM and ICAM, which regulate leukocyte adhesion to the endothelium, 33 and the expression of the CD40 ligand CD154, which is described in endothelial and smooth muscle cells, macrophages, platelets, and T lymphocytes and thought to contribute to the initial recruitment of inflammatory cells to damaged endothelium (for review, see work by Schonbeck and Libby 34 ). It was shown that the disruption of the CD154-CD40 system retarded the initiation of arterial plaque formation. 35 We observed a trend toward lower CD154 expression in endothelium and smooth muscle cells in mCRP-treated ApoE Ϫ/Ϫ mice compared with the other 2 groups. In addition, CD154 expression correlated with plaque size. Treatment with human mCRP at a distant injection site might have reduced the tumor necrosis factor-␣-related inflammatory process at the aortic site. The observation that enhanced plaque formation induced by nCRP was paralleled by increased VCAM and a trend toward increased ICAM expression supports the critical role of ICAM and VCAM found by others in hypercholesterolemic animal models. 36, 37 At first glance, the results presented here appear to be contradictory to reports in vitro. In those studies, mCRP triggered proinflammatory activities in isolated human neutrophils and endothelial cells, including increased production of monocyte chemoattractant protein-1, IL-8, ICAM, VCAM, and E-selectin. 18, 22, 38 In contrast, nCRP was without detectable effects on these signaling cascades. It was suggested that endothelial injury might expose the naturally occurring mCRP, leading to the attraction of neutrophils to the area of injury. Alternatively, mCRP may also be formed from nCRP at sites of injury or infection by some as-yet-unknown mechanism as part of the acute activation and/or resolution of the inflammatory process. 39 The fact that human mCRP-treated mice showed less plaque is not necessarily in contradiction to the aforementioned studies that addressed immediate responses (over minutes to hours) using isolated cells. The long-term effect of a stimulatory protein on the overall immune response in a live animal cannot be predicted precisely from isolated systems. Such opposite stimulatory and inhibitory actions, depending on the dose used, have been described for anti-CD3 monoclonal antibody effects on the T-cell receptor in vivo. 40 In an animal model of systemic lupus erythematodes, a single injection of 200 g SC of CRP prevented or reversed lupus nephritis. 41 Because IL-10 was required for this protection, we studied serum levels of this antiinflammatory cytokine with potent deactivating properties on both macrophages and T lymphocytes. 42 Although ApoE Ϫ/Ϫ mice generally had lower IL-10 levels than the C57BL/6 control mice, mCRP-treated ApoE Ϫ/Ϫ mice had higher IL-10 levels than the other 2 groups. Therefore, mCRP injections could be beneficial through upregulation of IL-10. Namiki et al 43 proposed IL-10 as a new therapeutic tool for the treatment of atherosclerosis. Gene transfer of IL-10 cDNA reduced atherosclerosis in male ApoE Ϫ/Ϫ mice and decreased serum levels of IFN-␥ associated with macrophage activation. Seven days after the last injection, we were unable to detect IFN-␥ in either ApoE Ϫ/Ϫ or C57BL/6 mice. Because of the limited availability of serum material, it was not possible to measure other proinflammatory or antiinflammatory cytokines.
In summary, we describe a model of early atherogenesis in which human nCRP accelerated atherosclerosis and mCRP partly prevented plaque formation. Results of IL-10 measurements are consistent with the interpretation that small amounts of mCRP could heighten normal immune surveillance in the mouse, slowing the process of atherosclerotic plaque formation. Immunostainings for CD154, VCAM, and ICAM may indicate that nCRP and mCRP influence the initial steps of atherogenesis differentially. Further studies are needed to elucidate the signaling cascade of mCRP and its relevance to the processes of atherosclerosis in humans.
